Effects of exenatide on XXXX in @entity6 .

@entity1 @entity455 @entity6 @entity1674 @entity450 @entity165 @entity412 @entity42652 @entity413 @entity5445
BACKGROUND: Basic studies have shown that @entity5445 ( @entity5445 ) analogs exert a direct protective effect on the vascular endothelium in addition to their indirect effects on postprandial @entity413 and lipid metabolism. @entity5445 analogs are also reported to inhibit @entity455 . This study examined whether the @entity5445 analog exenatide inhibits @entity455 in @entity1 with @entity6 ( @entity6 ). METHODS: Seventeen @entity1 with @entity6 underwent a meal tolerance test to examine changes in postprandial vascular endothelial function and in @entity413 and lipid metabolism, both without exenatide (baseline) and after a single subcutaneous injection of 10   g exenatide. Vascular endothelial function was determined using reactive @entity450 index (RHI) measured by peripheral arterial tonometry before and 120  min after the meal loading test. The primary endpoint was the difference in changes in postprandial vascular endothelial function between the baseline and exenatide tests. RESULTS: The natural logarithmically-scaled RHI (L_RHI) was significantly lower after the baseline meal test but not in the exenatide test. The use of exenatide resulted in a significant decrease in @entity1674 (TG) area under the curve and coefficient of variation (CV). The change in L_RHI correlated with changes in CV of @entity1674 and HDL- @entity165 . Multivariate analysis identified changes in @entity412 CV as the only determinant of changes in L_RHI, contributing to 41% of the observed change. CONCLUSIONS: @entity42652 inhibited @entity455 after the meal loading test, suggesting that exenatide has a multiphasic anti-atherogenic action involving not only @entity413 but also lipid metabolism. TRIAL REGISTRATION: ClinicalTrials.gov: UMIN000015699.
